The National Advisory Committee on Immunization continues to strongly recommend the use of mRNA COVID-19 vaccines (e.g. Moderna, Pfizer) due to the excellent protection they provide against severe illness and hospitalization. Novavax vaccine is a recombinant protein subunit COVID-19 vaccine that may be offered as a primary series to those 12 years of age or older who are not able or willing to receive an mRNA COVID-19 vaccine. A primary series of Novavax is two doses.
Novavax may be offered as a booster dose to people who are not willing or not able to receive an mRNA vaccine, regardless of which COVID-19 vaccines they may have already received. Health Canada authorized the use of Novavax as a booster dose in people 18 years and older on November 17, 2022.
Eligibility
- 12 years or older.
- No allergy to any of the vaccine ingredients.
- Not able or not willing to receive an mRNA COVID-19 vaccine (e.g. Moderna, Pfizer).
- For those getting their first or second dose of any COVID-19 vaccine:
- A recommended two months (56 days) have passed since your last COVID-19 vaccine. You must wait a minimum of one month (28 days).
- If you recently had COVID-19, we recommend that you wait two months (56 days) after you first got symptoms or after a positive test. For those who are immunocompromised or have a history MIS-C, please see Ontario guidance.
- For those getting a booster dose: six months (168 days) have passed since getting COVID-19 or since your last COVID-19 vaccine. The minimum interval is three months (84 days).
- If appointments fill up, KFL&A area residents will be prioritized. You may get a call cancelling your appointment if you are a resident outside of the KFL&A area.
Resources
-
COVID-19 Vaccine Information Sheet (ages 12 and older) - Ontario Ministry of Health and Long Term Care
- Summary of National Advisory Committee on Immunization (NACI) Statement - Public Health Agency of Canada
- Novavax Nuvaxovid COVID-19 vaccine - Government of Canada